Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Diseases
we target
Diseases we target
Leber Hereditary Optic Neuropathy (LHON)
Retinitis Pigmentosa (RP)
Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Clinical development Summary
Investors
Company Overview
Financial press releases
Investor Newsletters
Events & presentations
Stock information & Financial agenda
Governance
Documentation
Media
Press Releases
Year
All
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
General Assembly
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
04 February 2021
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates
19 January 2021
GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update
18 January 2021
GenSight Biologics Announces its 2021 Financial Calendar
13 January 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
10 December 2020
GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital
10 December 2020
GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine
15 November 2020
Article – EN
03 November 2020
GenSight Biologics reports validation of LUMEVOQ® Marketing Authorisation Application (MAA) by European Medicines Agency
22 October 2020
GenSight Biologics successfully raises €25 million in an oversubscribed private placement with US and European institutional investors
21 October 2020
GenSight Biologics launches a capital increase of approximately €25 million by means of an accelerated bookbuilding process
View previous 9 articles
1
…
7
8
9
10
11
12
13
14
15
16
17
…
24
View next 9 articles
Go back to the page of the page